Virtual Library

EP16.03-004 - Targeting SHP2 Reverts Oncogenic Mediated Resistance to KRAS-G12C Inhibition

EP16.03-005 - Australian Non-Small Cell Lung Cancer (NSCLC) Biomarker Testing Practices - A Survey of Medical Oncologists and Pathologists

EP16.03-031 - Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer Harboring Different EGFR Exon 19 Del/Delins Variants

EP16.03-032 - Structure-Based Classification of Chinese Patients with Non-Canonical EGFR-Mutant Non-Small Cell Lung Cancer

EP16.03-003 - Systematic Population-based Identification of NTRK Fusion Genes Among Hispanic Patients with Non-Small Cell Lung Cancer (NSCLC)

EP16.03-002 - Mechanisms of Resistance to First-line Osimertinib in Hispanic Patients with EGFR mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP∫)

EP16.03-009 - Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genyotyping

EP16.03-029 - SLIT2 Expression in NSCLC With Long-Term Response to Pemetrexed

EP16.03-010 - Molecular and Clinical Characterization of Lung Adenocarcinoma With Respect to Patient Age at Diagnosis

EP16.03-016 - Targetable Alterations in Non-Small Cell Lung Cancer According to Age and Sex

EP16.03-011 - The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity

EP16.03-012 - Novel Human-derived EML4-ALK Fusion cell lines identify ribonucleotide reductase RRM2 as a Target of Activated ALK in NSCLC

EP16.03-018 - Molecular Features of Subtypes Classified Based on Predominance and Components in Chinese Patients with Lung Adenocarcinoma

EP16.03-001 - High Frequency of KRAS Mutation, Uncommon EGFR Mutation and TMB-H in Xuanwei Female Patients With Lung Adenocarcinoma

EP16.03-013 - Psychological Distress and Beta-2 Adrenergic Receptor Expression in Non-small Cell Lung Cancer Cells

EP16.03-007 - Comprehensive Analysis of m6A-Related Gene Mutation Characteristics and Prognosis in Lung Adenocarcinoma

EP16.03-014 - Simultaneous Detection of FGFR Gene Aberrations in Squamous Non-small Cell Lung Cancer Using Targeted DNA- and RNA-based NGS

EP16.03-034 - Differential Prognostic Effect of EGFR Mutation According to Smoking Status and Pathologic Stage in Non-mucinous Lung Adenocarcinoma

EP16.03-026 - Metastasis Sites and Genomic Alterations in Advanced Non Small Cell Lung Cancer: A Retrospective Study

EP16.03-015 - Centrosome Amplification Is a Prognostic Indicator and Potential Therapeutic Vulnerability in Non-small Cell Lung Cancer

EP16.03-017 - Spatial Heterogeneity of Tumor Microenvironment of Lung Adenocarcinoma Associated With Genomic Alterations

EP16.03-006 - Genetic Characteristics of EGFR Concurrent Variants with RB1 and TP53 in NCSLC Patients

EP16.03-020 - High Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC in Never Smokers is Associated with Worse Prognosis

EP16.03-021 - Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)

EP16.03-022 - Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Sampling Is Sufficient for Lung Cancer Molecular Profiling

EP16.03-023 - KRAS Alterations, Clinicopathological Features and Co-occurring Drivers Associated with Prognosis in Advanced NSCLC Patients

EP16.03-024 - Cellworks Singula™ Therapy Response Index (TRI) Identifies Superior OS Outcomes for NSCLC Patients: myCare-203A

EP16.03-025 - Immunogenomics of Clinical Resistance to KRAS G12C Inhibition

EP16.03-027 - Routine Molecular Testing Using the TSO500+ NGS Panel in a Cohort of Patients with NSCLC

EP16.03-046 - Tumor Grade Associated Genomic Mutations in Chinese Patients with Lung Cancer

EP16.03-028 - Cancer Cells May be Re-sensitized to Tumor Treating Fields (TTFields) Through Inhibition of the PI3K/AKT/mTOR Pathway

EP16.03-019 - Landscape of EGFR Extracellular Domain Mutations in Advanced Non Small Cell Lung Carcinoma

EP16.03-035 - Driver Mutations on Metastatic NSCLC - Experience in a Secondary Center

EP16.03-036 - Clinical and Genomic Features of HER2 exon 20 Insertion Mutations in East Asian NSCLC

EP16.03-037 - Poor Prognosis of Patients with EGFR Mutations Left behind by Selective Detection in NSCLC

EP16.03-038 - Single-cell Analyses Reveal Tumor Microenvironment Differences between EGFR 19del and L858R mutations in Lung Adenocarcinoma

EP16.03-039 - Characterizing SHPRH as a Novel Tumor Suppressor Gene in Lung Adenocarcinoma

EP16.03-047 - Genomic Landscape of Squamous Cell Carcinoma Lung in an Indian Cohort

EP16.03-040 - Biomarkersatlas.com: the Italian NSCLC Precision Medicine Knowledge Data Base

EP16.03-042 - BET Inhibitors Stimulate NK Cytotoxic Activity in NSCLC through Attenuation of YAP/TAZ and SMAD3 Transcriptional Programs

EP16.03-041 - Single Cell RNA Sequencing Reveals Phenotypic Predispositions to Developing Lung Cancer in Never-Smokers

EP16.03-043 - Comprehensive Genomic Profiling of Tumor Mutational Burden-high in Chinese Lung Cancer Patients

EP16.03-008 - The Landscape of NFE2L2 Alteration in Chinese Lung Cancer Patients

EP16.03-045 - The Effect of Vascular Endothelial Growth Factor Gene Polymorphisms in the Clinical Outcome of Patients with Lung Cancer

EP16.03-044 - Genomic Evidence Depicting Clonal Evolution of Lung Adenosquamous Carcinoma

EP16.03-033 - Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups

EP16.04-017 - Lineage Switching and Tumor Microenvironment Roles of Tumor Suppressors in Autochthonous Lung Cancer Models

EP16.04-018 - DNA Mismatch Repair in Lung Adenocarcinoma in Morocco

EP16.04-019 - Impact of Chemotherapy on Tridimensional Multicellular Non-small Cell Lung Cancer Spheroids With Microenvironment Cells

EP16.04-010 - Histological and Genetic Parental Tumor Characteristics are Conserved in Patient-derived Non-small Cell Lung Cancer Organoids

EP16.04-020 - Dysregulation of 14-3-3 Signaling Adapters in Lung Adenocarcinoma, New Insights Into the Impact on Cancer Cell Biology

EP16.04-007 - ALDH2 Downregulation, Aberrant DNA Methylation, and Loss of Stemness Pathways as an Enhanced Biomarker in Lung Adenocarcinoma

EP16.04-027 - Identification of Optimal Internal Reference Gene to Analyze the Anticancer Effects of Statins in Lung Cancer Cells

EP16.04-026 - Effectiveness of Atorvastatin and SR-12813 Combination in Statin-resistant and Statin-sensitive Lung Cancer Cell Lines

EP16.04-024 - HMGB1-mediated Autophagy Promotes Gefitinib Resistance in Human Non-small Cell Lung Cancer

EP16.04-031 - Connexin 43 Overexpression Induces Angiogenesis in Vitro Following Phosphorylation at Ser279 in its C Terminus

EP16.04-032 - Indoleamine 2,3-dioxygenase 1 (IDO1) Blood Metabolites May Improve Predictive Accuracy for Radiation Pneumonitis

EP16.04-030 - Cancer-Associated Fibroblasts Attenuate DNA Damage Repair by Promoting Glycolysis in Non-small Cell Lung Cancer

EP16.04-001 - The Role of Stromal PDGFRβ-activation in NSCLC

EP16.04-002 - Combining Patient-Derived Xenografts and Barcoding Technology to Evaluate Response to Targeted Therapies in ALK+NSCLC

EP16.04-004 - Impact of Gender on Cellular Response to Cigarette Smoke Extract

EP16.04-003 - High Dimensional Spatial Profiling of the NSCLC Tumour Microenvironment

EP16.04-005 - Investigating the Side Effects of Docetaxel on Rat Lung and Heart

EP16.04-006 - A Novel Orthotopic Xenograft Mouse Model to Study Lung Cancer-Associated Fibroblasts and Lymphangiogenesis

EP16.04-008 - Cytotoxic Effects of Carnosic Acid Are Mediated by Induction of Autophagy and Activation of Sestrin-2/LKB1/AMPK Signalling in H1299 NSCLC Cells

EP16.04-016 - Overexpression of CEACAM6 Activates Src-FAK Signaling and Inhibits Anoikis, through Homophilic Interactions in Lung Adenocarcinomas

EP16.04-029 - Downregulation of PHLPP2 Induced by Radiation Promotes GPX4-mediated Ferroptosis Defense and Radioresistance in Lung Cancer

EP16.04-028 - PHLPP2 Regulates Ferroptosis Through Nrf2 Pathway to Affected Cell Cycle and Apoptosisin Lung Squamous Cell Carcinoma

EP16.04-009 - The Proliferative Effect of 27-Hydroxycholesterol as a Selective Estrogen Receptor Modulator on Pathology of NSCLC

EP16.04-011 - Sex Hormone Signalling in Lung Adenocarcinoma Limits Tumour Virulence

EP16.04-012 - Retrospective Analysis of Non-Small Cell Lung Cancer with Mucinous Histology Subtype

EP16.04-025 - Statins Suppress SOAT1 Expression & Reduce Cholesterol Esterification in Statin-sensitive Lung Cancer Cells

EP16.04-013 - Spatial Multi-Omics Landscape of Radiologically Preinvasive/Invasive Lesion in Part-Solid Lung Adenocarcinoma

EP16.04-014 - NTRK in Lung Cancer Patients with History of Hodgkin's Lymphoma

EP16.04-015 - Chemotherapy Upregulates Programmed Cell Death Ligand 1 Expression in Non-Small Cell Lung Cancer Cell Lines and Patient-Derived Organoid Models

EP16.04-022 - Prognosis of Epithelial-Mesenchymal Transition-Related lncRNA Profile in LUSC Patients

EP16.04-021 - Chromatin Remodeling Drives Lung Pre-malignancy and is a Target for Prevention

ES01.01 - Session Introduction

10:45 - 10:46  |  Author(s): Mario Silva

Session Moderator

10:45 - 10:45  |  Author(s): Mario Silva

Session Moderator

10:45 - 10:45  |  Author(s): Marjolein Heuvelmans

ES01.02 - Session Introduction

10:46 - 10:47  |  Author(s): Marjolein Heuvelmans

ES01.03 - Scalability of Excellence: Continuous Refinement of Screening Scheme

10:47 - 10:59  |  Author(s): Annette Maree McWilliams

ES01.04 - Strategies for Recruitment: Risk Profile, Engagement, Adherence

10:59 - 11:11  |  Author(s): Hilary A Robbins

ES01.05 - LCS: Pulmonary and Extrapulmonary Findings

11:11 - 11:23  |  Author(s): Sam Janes

ES01.06 - US-Preventive Services Task Force LCS Recommendations in Community Based Health Care Systems

11:23 - 11:35  |  Author(s): Katharine Rendle

ES01.07 - Live Q&A

11:35 - 11:45

ES02.01 - Session Introduction

10:45 - 10:46  |  Author(s): Marina Chiara Garassino

ES02.02 - Session Introduction

10:46 - 10:47  |  Author(s): Christian Grohe

ES02.03 - Impact of the COVID-19 Pandemic on Lung Cancer Diagnosis and Screening

10:47 - 10:59  |  Author(s): Betty Tong

ES02.04 - Impact of the COVID-19 Pandemic on Surgery

10:59 - 11:11  |  Author(s): Leanne Ashrafian

Session Moderator

10:59 - 11:11  |  Author(s): Marina Chiara Garassino

Session Moderator

10:59 - 11:11  |  Author(s): Christian Grohe

ES02.05 - Impact of the COVID-19 Pandemic on Radiotherapy

11:11 - 11:23  |  Author(s): Umberto Ricardi

ES02.06 - Impact of the COVID-19 Pandemic on Systemic Treatment

11:23 - 11:35  |  Author(s): Wilfried Ernst Erich Eberhardt

ES02.07 - Live Q&A

11:35 - 11:45

ES03.01 - Session Introduction

10:45 - 10:46  |  Author(s): Daniel SW Tan

ES03.02 - Session Introduction

10:46 - 10:47  |  Author(s): Hans Hoffmann

ES03.03 - Synchronous Oligometastatic NSCLC 2022 Where Are We Now

10:47 - 10:59  |  Author(s): Jeffrey Dee Bradley

Session Moderator

10:47 - 10:59  |  Author(s): Hans Hoffmann

Session Moderator

10:47 - 10:59  |  Author(s): Daniel SW Tan

ES03.04 - Concept 1: Brain Only Disease

10:59 - 11:11  |  Author(s): Paul Martin Putora

ES03.05 - Concept 2: Bulky Thoracic Disease

11:11 - 11:23  |  Author(s): Ben Solomon

ES03.06 - Concept 3: cT1bN0, Single Adrenal Met: Surgery or Radiotherapy; Sequencing with Systemic Treatment

11:23 - 11:35  |  Author(s): Isabelle Opitz

ES03.07 - Live Q&A

11:35 - 11:45

MA01.01 - Session Introduction

10:45 - 10:46  |  Author(s): Fabio Pagni

Session Moderator

10:45 - 10:46  |  Author(s): Fabio Pagni

Session Moderator

10:45 - 10:46  |  Author(s): Ferdinandos Skoulidis

MA01.02 - Session Introduction

10:46 - 10:47  |  Author(s): Ferdinandos Skoulidis

MA01.03 - Exploiting DNA Methylation for Classification of SCLC Subtypes from Liquid Biopsies Using a Robust Machine Learning Approach

10:47 - 10:52  |  Author(s): Simon Heeke

MA01.04 - Molecular Subtypes of Surgically Resected Small Cell Lung Cancer: Expression Pattern and Prognostic Relevance

10:52 - 10:57  |  Author(s): Zsolt Megyesfalvi

MA01.05 - Immuno-microenvironment (TIME) Heterogeneity of Small Cell Lung Cancer (SCLC) Stratified by Molecular Subtypes

10:57 - 11:02  |  Author(s): Jiyan DONG

MA01.06 - Discussant

11:02 - 11:12  |  Author(s): Kenneth John O'Byrne

MA01.07 - From Molecular to Histological Characterization of Lung Carcinoids via Computer Vision and Spatial Genomics

11:12 - 11:17  |  Author(s): émilie Mathian

MA01.08 - Impact of [18F]FDG PET/CT-derived Metabolic Parameters on Outcomes in Extensive-stage SCLC

11:17 - 11:22  |  Author(s): Elisa Andrini

MA01.09 - Characterising Aggressive Pulmonary Carcinoids Through Integrative Omics Analysis Within the lungNENomics Project

11:22 - 11:27  |  Author(s): Alexandra Sexton-Oates

MA01.10 - Discussant

11:27 - 11:37  |  Author(s): Michael Boyer

MA01.11 - Live Q&A

11:37 - 11:45

Session Moderator

10:45 - 10:45  |  Author(s): Erik Thunnissen

MA02.01 - Session Introduction

10:45 - 10:46  |  Author(s): Erik Thunnissen

Session Moderator

10:45 - 10:45  |  Author(s): Rafael Rosell

MA02.02 - Session Introduction

10:46 - 10:47  |  Author(s): Rafael Rosell

MA02.03 - The Evolution of Lung Neuroendocrine Tumors

10:47 - 10:52  |  Author(s): Nicolas Alcala

MA02.04 - Molecular Drivers and Therapeutic Targets for Neuroendocrine Transformation in Lung Cancer

10:52 - 10:57  |  Author(s): Triparna Sen

MA02.05 - Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations

10:57 - 11:02  |  Author(s): Jie Huang

MA02.06 - Discussant

11:02 - 11:12  |  Author(s): Yuko Minami

MA02.07 - Aurora A Kinase Inhibition with VIC-1911Potentiates KRASG12C Inhibitor and Overcomes Resistance to Sotorasib in Lung Cancer

11:12 - 11:17  |  Author(s): Jong Woo Lee

MA02.08 - Trametinib Inhibition of MEK1 2 Upregulates PD-L1 Expression in KRAS-Mutant NSCLC Through ID1 Downregulation

11:17 - 11:22  |  Author(s): Ander Puyalto

MA02.09 - Impact of Baseline Clinicopathologic and Genomic Features on Outcomes to KRAS G12C Inhibitors in Patients with NSCLC

11:22 - 11:27  |  Author(s): Giuseppe Lamberti

MA02.10 - Discussant

11:27 - 11:37  |  Author(s): Sally Lau

MA02.11 - Live Q&A

11:37 - 11:45

OA01.01 - Session Introduction

10:45 - 10:46  |  Author(s): Gyula Ostoros

Session Moderator

10:45 - 10:45  |  Author(s): Gyula Ostoros

Session Moderator

10:45 - 10:45  |  Author(s): Oscar Arrieta

OA01.02 - Session Introduction

10:46 - 10:47  |  Author(s): Oscar Arrieta

OA01.03 - Lung Cancer in Victoria: Association Between Stage-Specific Receipt of Guideline-Concordant Treatment and Survival

10:47 - 10:57  |  Author(s): Sanuki Tissera

OA01.04 - Persisting Gaps in Optimal Care of Stage III Non-Small Cell Lung Cancer: An Australian Patterns of Care Analysis

10:57 - 11:07  |  Author(s): Katrina L Woodford

OA01.05 - Socio-economic Inequalities in NSCLC Treatment During the Era of Tumour Biomarker Guided Therapy: A Population-based Study

11:07 - 11:17  |  Author(s): Ruth Pamela Norris

OA01.06 - Project PEER: A Longitudinal Real-World Study to Understand the Experience of Patients With Lung Cancer and Their Caregivers

11:17 - 11:27  |  Author(s): Upal Basu Roy

OA01.07 - Discussant

11:27 - 11:37  |  Author(s): Tatiane Caldas Montella

OA01.08 - Live Q&A

11:37 - 11:45

ES04.01 - Session Introduction

12:00 - 12:01  |  Author(s): Torsten Gerriet Blum

Session Moderator

12:00 - 12:00  |  Author(s): Torsten Gerriet Blum

Session Moderator

12:00 - 12:00  |  Author(s): Ricardo Sales Santos

Session Moderator

12:00 - 12:00  |  Author(s): Mónica Castro

ES04.02 - Session Introduction

12:01 - 12:02  |  Author(s): Ricardo Sales Santos

ES04.03 - Session Introduction

12:02 - 12:03  |  Author(s): Mónica Castro

ES04.04 - Europe: International Network for Continuous Evidence-Based Optimization of LCS

12:03 - 12:15  |  Author(s): Matthijs Oudkerk

ES04.05 - Lung Cancer Screening in Asia for Individuals Without a Smoking History

12:15 - 12:27  |  Author(s): Pan Chyr Yang

ES04.06 - Argentinean National Consensus on LCS; Barriers and Challenges to Implement It in the Context of Latinoamerica LCS Situation

12:27 - 12:39  |  Author(s): Iris Boyeras Navarro

ES04.07 - Gender Differences in Lung Cancer Screening

12:39 - 12:51  |  Author(s): Narjust Florez (Duma)

ES04.08 - Live Q&A

12:51 - 13:00